Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Curevac N.V. (NQ: CVAC )

2.830 -0.030 (-1.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Curevac N.V.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Via ACCESSWIRE
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Via ACCESSWIRE
CureVac Announces Update to the Management Team
Via ACCESSWIRE
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
Via ACCESSWIRE
Why Shares of CureVac Jumped This Week
The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate. 
Via The Motley Fool
Earnings Preview: CureVac
Via Benzinga
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
Why CureVac Stock Leaped 12% Higher Today
The war on cancer advances with the German company's latest clinical development. 
Via The Motley Fool
DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 250 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
Via ACCESSWIRE
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
Via ACCESSWIRE
CureVac Announces Voting Results of General Meeting
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023
Via Benzinga
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
Via ACCESSWIRE
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
Via ACCESSWIRE
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
Via ACCESSWIRE
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
Via ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
Via ACCESSWIRE
CureVac Announces Voting Results of Extraordinary General Meeting
Via ACCESSWIRE
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees
Shares crumbled after Moderna's flu shot outperformed in just one flu strain. 
Via Investor's Business Daily
Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents
Via Benzinga
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
Via ACCESSWIRE
Why CureVac Shares Are Nosediving Today
CureVac BV (NASDAQ: CVAC) shares are trading lower by 13.99% to $9.10 during Tuesday's session after the company announced a proposed public offering of common stock. What Happened? 
Via Benzinga
Why Bed Bath & Beyond Fell Almost 30%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
CureVac Announces Proposed Public Offering of Common Shares
Via ACCESSWIRE
CureVac Welcomes Myriam Mendila as New Chief Development Officer
Via ACCESSWIRE
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
Via ACCESSWIRE
CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs
Via Benzinga
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.